Going forward...

On 30th August 2018, Cynata announced:

"Cynata CYP-001 Stem Cell Therapy Meets All Safety and Efficacy Endpoints in Phase 1 Trial in GvHD"

What it really says is:

"Clinically proven Cymerus technology enables economical large-scale manufacturing of safe allogeneic MSCs for a large number of devastating disease targets"

According to a Shaw and Partner presentation from 05/05/17:

"Positive results from CYP’s GvHD trial in 2017 should provide theconfirmatory evidence. This will open the Cymerus production method to commercialuses for multiple indications across therapeutic markets worth billions."

They listed the following remaining risks though:

Other risks weconsider to be less significant include: i) delays in clinical trial enrolment; ii) an inabilityto negotiate additional strategic partnerships; and iii) poor results from clinical trials."

So... "ii" - it is management's turn to show their ability to negotiate deals, now that safety of our Cymerus process has been proven, there is no risk of an immediate cash deficit and we have two major shareholders aboard (one of them also being our well-connected business partner).

No more "hide and seek", all eyes are now on YOU to deliver!